免疫检查点抑制剂单药或联合其他药物治疗实体瘤的早期死亡风险比较评估:系统综述与Meta分析
该系统综述与Meta分析纳入56项随机对照试验(40,215例受试者、14种癌症类型),比较免疫检查点抑制剂(ICI)单药或联合非ICI治疗与对照组的早期死亡(治疗前3个月内死亡)风险。ICI单药组早期死亡风险显著高于非ICI治疗(RR:1.29,95%CI 1.05-1.57),ICI联合组低于非ICI治疗(RR:0.81,95%CI 0.73-0.90),ICI单药组高于ICI联合组(RR:1.57,95%CI 1.26-1.95)。
要点
- ICI单药治疗较非ICI治疗显著增加早期死亡风险(RR:1.29,95%CI 1.05-1.57)。
- ICI联合其他非ICI治疗较非ICI治疗降低早期死亡风险(RR:0.81,95%CI 0.73-0.90)。
- 胃癌与尿路上皮癌早期死亡风险较高,PD-L1表达及ICI药物类别与早期死亡无关。
核心结论
- 一线ICI治疗期间的早期死亡是跨实体瘤的临床相关现象,不能由PD-L1表达预测,但可通过在ICI基础上联合其他治疗加以预防。
研究设计与样本
- 系统综述与Meta分析,纳入比较ICI单药(ICI-only组)或ICI联合其他非ICI治疗(ICI-OT组)试验组与接受非ICI治疗对照组的随机对照试验;早期死亡定义为治疗前3个月内死亡;风险比(RR)采用随机效应模型合并。
- 共纳入56项随机对照试验,40,215例受试者,涵盖14种癌症类型。
主要发现
- ICI-only组早期死亡发生率为14.2%,ICI-OT组为6.7%。
- ICI-only组较非ICI治疗对照组早期死亡风险显著增加(RR:1.29,95%CI 1.05-1.57)。
- ICI-OT组较非ICI治疗对照组早期死亡风险降低(RR:0.81,95%CI 0.73-0.90)。
- ICI-only组早期死亡风险显著高于ICI-OT组(RR:1.57,95%CI 1.26-1.95)。
- 胃癌与尿路上皮癌早期死亡风险较高;PD-L1表达和ICI药物类别与早期死亡无关联。
临床怎么用
- 原文结论指出早期死亡不能由PD-L1表达预测,但可通过在ICI基础上联合其他治疗加以预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The early crossing of survival curves in randomised clinical trials (RCTs) with immune checkpoint blockers suggests an excess of mortality in the first months of treatment. However, the exact estimation of the early death (ED) rate, the comparison between ED upon immune checkpoint inhibitors (ICI) alone or in combination with other agents and the impact of tumour type, and PD-L1 expression on ED are unknown. METHODS: RCTs comparing ICI alone (ICI-only group) or in combination with other non-ICI therapies (ICI-OT group) (experimental arms) versus non-ICI treatments (control arm) were included. ED was defined as death within the first 3 months of treatment. The primary outcome was the comparison of ED between experimental and control arms, and the secondary outcome was the comparison of ED risk between ICI-only and ICI-OT. ED rates estimated by risk ratio (RR) were pooled by random effect model. RESULTS: A total of 56 RCTs (40,215 participants, 14 cancer types) were included. ED occurred in 14.2% and 6.7% of patients in ICI-only and ICI-OT groups, respectively. ED risk significantly increased with ICI-only (RR: 1.29, 95% CI 1.05-1.57) versus non-ICI therapies, while it was lower with ICI-OT versus non-ICI treatments (RR: 0.81, 95% CI 0.73-0.90). ED risk was significantly higher upon ICI-only compared to ICI-OT (RR: 1.57, 95% CI 1.26-1.95). Gastric and urothelial carcinoma were at higher risk of ED. PD-L1 expression and ICI drug classes were not associated with ED. CONCLUSIONS: ED upon first-line ICI is a clinically relevant phenomenon across solid malignancies, not predictable by PD-L1 expression but preventable through the addition of other treatments to ICI.
引用
- Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022. PMID: 36368251. doi:10.1016/j.ejca.2022.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。